Nektar Therapeutics
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ITH0.F | 6YG.MU | CRVS | ACRS | AKTS | ARTV | |
|---|---|---|---|---|---|---|
| Market cap | 1.15B | 1.31B | 889.16M | 570.34M | 845.42M | 206.32M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | — | -9.9 | -5.1 | -7.1 | -2.1 |
| Price/book | 1.4 | 3.5 | 3.9 | 4.1 | 1.7 | 0.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −31.83% | −6.85% | +30.54% | +65.49% | −33.30% | +22.09% |
| Today | +1.54% | −2.99% | +7.53% | −1.60% | +1.74% | +0.48% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ITH0.F news ›Nektar Therapeutics: Focus Returns To The Strengths Of The Company
Nektar’s rezpegaldesleukin enters phase 3 in atopic dermatitis, with Q1 2027 data ahead. Discover more here on NKTR and our bullish thesis for the stock. - Nektar Therapeutic's rezpegaldesleukin is now in phase 3 trials in atopic…
Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink Partners
Posted by Sarita Garza on Oct 13th, 2026 Leerink Partners assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research report released on Monday morning, Marketbeat Ratings reports. The brokerage issued an…
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target
BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00. The price target implies an upside of 336.3% from the Oct 8 close of $40.80. Positive Initial Legal Outcomes: The favorable outcome of the…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com1
- themarketsdaily.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.